COVID-19 has exposed the limits of the pharmaceutical market model. This week, patent law expert Tahir Amin joins the show to explain why vaccine development needs new incentives.
Tahir Amin is an attorney dedicated to reshaping patent law to better serve the public. He is the Co-Founder and Co-ED of the Initiative for Medicines, Access, and Knowledge (I-MAK), a global nonprofit organization of attorneys, scientists, and health experts working on systemic changes to intellectual property and the political economy of pharmaceutical innovation.
Twitter: @realtahiramin
Further reading:
Covid-19 has exposed the limits of the pharmaceutical market model: https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/
No vaccine in sight: https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system
Democrats punt on drug-pricing overhaul in virus relief measure: https://news.bloomberglaw.com/health-law-and-business/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure
Website: http://pitchforkeconomics.com/
Twitter: @PitchforkEcon
Instagram: @pitchforkeconomics
Nick’s twitter: @NickHanauer
This post was originally published on Pitchfork Economics with Nick Hanauer.
